Cure Today7h
Ficerafusp Alfa Trial Begins for Recurrent/Metastatic Head and Neck Cancer
Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with ...
Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...
Pharmabiz19h
Merus’ petosemtamab receives US FDA breakthrough therapy designation for 1L PD-L1 positive head and neck squamous cell carcinoma
Utrecht, The Netherlands Thursday, February 20, 2025, 15:00 Hrs [IST] ...
Targeted Oncology1d
Discussing Lung Cancer NGS Testing and EGFR Treatment Strategies
During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their ...
Ocean Biomedical advances in cancer immunotherapy
PROVIDENCE, RI - Ocean Biomedical (NASDAQ: OCEA) has announced research findings that show its immunotherapy candidates can work synergistically with tyrosine kinase inhibitors (TKIs), potentially ...
Endocrinology Advisor9d
January 2025 Recap: Drug Pipeline Updates
The table below is a review of notable updates that occurred in January 2025 for investigational products in development.
The Bakersfield Californian9d
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 ...
Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the ...
rheumatologyadvisor2d
Obinutuzumab Increases Complete Renal Response in Lupus Nephritis
Obinutuzumab B-cell depleting therapy is more effective than standard care in treating patients with active proliferative lupus nephritis.